NIDA Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) (R41, R42, R43 and R44) Notice: Major Programmatic Priorities

Notice Number: NOT-DA-11-020

Key Dates

Release Date:  May 27, 2011

Issued by

National Institute on Drug Abuse (NIDA)


The purpose of this notice is to alert the field to high program priorities relevant to the SBIR and STTR program  of  the National Institute on Drug Abuse (NIDA).

The SBIR/STTR program is intended to meet, among others, the following goals: strengthen the role of small business in meeting Federal research or research and development (R/R&D) needs; increase the commercial application of Federally-supported research results; and improve the return on investment from Federally-funded research.

In this Notice, NIDA emphasizes its need to discover, evaluate and develop medications (both small molecules and biologics) to treat substance use disorders (SUDs).  As such, this Notice underscores the importance of fostering research through NIDA SBIR/STTR Program aimed at the research and development of medications for SUD, as well as research aimed at modernizing the drug discovery and development toolkit.

Specifically, this Notice underscores the high programmatic priority given to research that seeks to achieve these goals in the following ways:

1)  Drug discovery and development-enabling activities: Development of innovative technologies, methods or tools, including but not limited to:

2)  Drug discovery and development activities: Application of emerging and existing technologies and platforms to SUD drug development. Medical products with potential to minimize drug seeking, compulsive behavior, and/or addictive processes are strongly encouraged.  Examples might include, but are not limited to:

NIDA Program Descriptions and Research Topics included in the 2011 SBIR and STTR Omnibus Solicitations of the NIH, CDC, FDA and ACF (PA-11-097 and PA-11-096, topic description at, applicable to NIDA opportunities only)which are not aimed at development of medications for substance-use disorders or at modernizing the drug discovery and development toolkit, will have low program priority.


Please direct all inquiries to:

Elena Koustova, PhD, MBA
National Institute on Drug Abuse (NIDA)
National Institutes of Health (NIH)
6001 Executive Blvd., Room 4286 (Suite 4282)
Bethesda, MD 20892-9555
Tel: 301-496-8768
Fax: 301-594-6043

Kristopher Bough, PhD
Program Officer, Medications Research Grants Branch (MRGB) 
Div. of Pharmacotherapies and Medical Consequences of Drug Abuse
National Institute on Drug Abuse (NIDA)
National Institutes of Health (NIH)
6001 Executive Blvd., Room 4153, MSC 9550
Bethesda, MD 20892
Tel: 301-443-9800

Weekly TOC for this Announcement
NIH Funding Opportunities and Notices

Office of Extramural Research (OER) - Home Page Office of Extramural
Research (OER)
  National Institutes of Health (NIH) - Home Page National Institutes of Health (NIH)
9000 Rockville Pike
Bethesda, Maryland 20892
  Department of Health and Human Services (HHS) - Home Page Department of Health
and Human Services (HHS) - Government Made Easy

Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.